CClinicalTrials.gg
Not yet recruitingNCT07591623Updated May 18, 2026

OCRA Distress & Unmet Needs

An interventional study of Surveys in Gynecologic Cancer, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a prospective longitudinal cohort study with an embedded intervention. It follows participants with gynecologic malignancies and their informal caregivers over a 6-month period to assess caregiver distress, NMDOH, and patient outcomes.

Read the detailed description

Primary Objectives:

Caregivers of patients with gynecologic cancers are at risk for significant distress, which is further impacted by NMDOH. Although caregiver distress affects patient outcomes, it is not routinely measured or addressed in the clinical setting, and little is known about disparities in caregivers' distress and burden in a diverse gynecologic cancer population.

We, therefore, propose the following objectives:

  1. To measure distress and define the NMDOH needs of caregivers of patients with gynecologic cancers
  2. To address unmet needs of gynecologic cancer caregivers through a semi-automated system to navigate caregivers to NMDOH and caregiving resources
  3. To evaluate changes over time in caregivers' unmet needs and distress following receipt of a semi-automated, targeted caregiver resource navigation (CRN) system, and to explore associations between changes in caregiver needs/distress and patients' cancer-related outcomes and distress.
02

Conditions studied

  • Gynecologic Cancer
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

This study will include participants from two categories:

Patients:

  1. Must be at least 18 years old
  2. Must read and speak English or Spanish
  3. Participants must have access to the internet via a smartphone, tablet, or computer (public or private), or have reliable access to a telephone to communicate with the study coordinator.
  4. Patient presenting for initial or recurrence chemotherapy treatment for management of a gynecologic malignancy (cancer of the ovary, uterus, cervix, vulva, vagina, peritoneum, or fallopian tube)
  5. No physical, psychological, or cognitive impairments that would preclude participation and ability to understand the consent statement

Caregivers:

  1. Must be at least 18 years old
  2. Must read and speak English or Spanish
  3. Participants must have access to the internet via a smartphone, tablet, or computer (public or private), or have reliable access to a telephone to communicate with the study coordinator.
  4. Must be an identified caregiver of an enrolled patient
  5. No physical, psychological, or cognitive impairments that would preclude participation and ability to understand the consent statement

The study will include patients with no caregiver, and only one caregiver may enroll per patient.

Exclusion criteria

Exclusion Criteria:

Patients:

1. Unwilling or unable to proceed beyond the consent statement step Caregivers

1. Unwilling or unable to proceed beyond the consent statement step

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Patient-Caregiver

    This arm includes participants with gynecologic malignancies who identify and enroll with a caregiver. Both participants and caregivers will complete baseline, 3-month, and 6-month assessments. Caregiver distress and NMDOH needs will be evaluated at baseline, and results will be used to guide the provision of Community Resource Navigation (CRN).

    Other: Surveys

  • Experimental
    Patient Without a Caregivers

    This arm includes patients with gynecologic malignancies who do not identify or enroll with a caregiver. These participants will complete the same assessment timepoints (baseline, 3 months, and 6 months). Data from this group will serve as a comparison to evaluate differences in outcomes relative to patients with caregivers, including the impact of caregiver presence, distress levels, and NMDOH burden.

    Other: Surveys

Interventions

  • OtherSurveys

    Study surveys will be administered primarily in REDCap, or with the help of a coordinator (i.e. mailing surveys, over the phone, or with a tablet during clinic visits) if assistance is needed.

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
  • UT MD Anderson
    Houston, Texas 77030, United States
    • Abigail Smith Zamorano, MD · Contact · aszamorano@mdanderson.org · 713-792-9938
    • Abigail Smith Zamorano, MD · Principal investigator
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07591623
Lead sponsor
M.D. Anderson Cancer Center
Collaborators
Ovarian Cancer Research Alliance (OCRA)
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
May 18, 2026

Study contacts

Abigail Smith Zamorano, MD
Contact
aszamorano@mdanderson.org
713-792-9938
Abigail Smith Zamorano, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion